Navigation Links
New Generation Disinfecting Products to be Launched in Direct Sales Channel
Date:5/24/2010

DALLAS, May 24 /PRNewswire/ -- An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.

The first product, IV-7 Ultimate Germ Defense™, is a revolutionary, patented, broad-spectrum germ-killing treatment for hard surfaces.  It kills viruses, bacteria and fungi in as quickly as 30 seconds, using the first new disinfectant technology approved by the EPA in 30 years.

IV-7 has no odor or fumes, does not cause skin irritation, and creates an invisible barrier of protection that continues killing germs for 24 hours.  

It will be brought to the consumer market through a new direct selling company called IV-7 Direct, using a multi-level sales model.  Independent sales representatives will earn commissions selling the product and also from the sales of people who they enlist into the business.

John Rochon, former chairman of Mary Kay Inc. and a veteran of over 20 years in the direct selling industry, is heading IV-7 Direct, which is part of Dallas-based Richmont Holdings.  A related company, Richmont Sciences, is the sales and marketing arm of IV-7's manufacturer, Pure Biosciences of San Diego ( PURE).  

"We have an obligation to get this product into the war on germs as quickly as possible, to protect our loved ones and save lives," said Mr. Rochon.

"IV-7 is too special to put on store shelves.  Through the person-to-person contact of direct selling, we can show consumers how these products are different and spread the word quickly."  

"When I decided to return to the direct selling industry, I wanted to approach it in a new way.  I wanted a new business model that did two things:  First, get this product into the hands of millions of people quickly without a multi-million dollar advertising campaign; Second, give sellers a unique binary and unilevel compensation plan that can replenish the savings they've lost in the recession."

IV-7's patented formula is powered by silver dihydrogen citrate (SDC), which has been proven effective against viruses, bacteria and fungi including H1N1, MRSA, Salmonella, E. coli, Norovirus, Influenza A, VRE, Campylobachter jejuni, Staphylococcus aureus and other pathogens.  

PURE is developing additional uses for SDC in areas such as personal care products, pharmaceuticals and food processing.  Additional products will be added to the IV-7 Direct lineup.


'/>"/>
SOURCE IV-7 Direct
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
2. Quantum move toward next generation computing
3. Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition
4. Argonne to host next generation battery symposium May 3-4
5. Cerealus Announces Licensing Agreement for Bio-Based Ceregel™, A Next Generation Strength and Retention System
6. Ambry Genetics Launches First X-Linked Mental Retardation Diagnostics Using Next Generation Sequencing
7. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
8. Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society
9. Caliper Life Sciences Launches LabChip(R) XT for Next Generation Sequencing Applications
10. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
11. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
Breaking Biology Technology:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
Breaking Biology News(10 mins):